Adams Respiratory Therapeutics Inc

Adams Respiratory Therapeutics — Q3 FY2006 Earnings Presentation

13 slides from Adams Respiratory Therapeutics's earnings presentation, May 11, 2006

  1. Slide 1: Fiscal 2006 Third Quarter Earnings Conference Call

    Slide 1: Fiscal 2006 Third Quarter Earnings Conference Call

    Fiscal 2006 Third Quarter Earnings Conference Call

  2. Slide 2: Solid Financial Performance

    Slide 2: Solid Financial Performance

    Solid Financial Performance (in millions) Net Revenues Pretax Income +126% Pretax Income +13%* YoY Growth 161% 12-Months Ended June 30 9-Months Ended March 31 3-Months Ended March 31 YoY Growth 54% YoY Growth 29% Pretax Income +64% *Includes a one-time pretax charge of $1.5 million or $0.03 per dilu

  3. Slide 3: Fiscal 2006 Third Quarter Net Sales

    Slide 3: Fiscal 2006 Third Quarter Net Sales

    Fiscal 2006 Third Quarter Net Sales $51.9 MM +20% $18.3 MM +28% $4.7 MM Launched 10/05 $1.2 MM Launched 03/06

  4. Slide 4: Mucinex: Market Share Gains

    Slide 4: Mucinex: Market Share Gains

    Mucinex(r): Market Share Gains Source: Information Resources, Inc. (IRI) weekly consumption data thru 3/19/06 (dollar sales) in c/c/a/s category. End of season Beginning of season 0.00% 1.00% 2.00% 3.00% 4.00% 5.00% 6.00% 7.00% 8.00% 9.00% 10.00% 9/12/2005 9/19/2005 9/26/2005 10/3/2005 10/10/2005 10

  5. Slide 5: Mucinex Annual Market Share Rapidly Expanding

    Slide 5: Mucinex Annual Market Share Rapidly Expanding

    Mucinex(r) Annual Market Share Rapidly Expanding 10-31-04 4-24-05 10-30-05 4-23-06 1.73 4.21 5.60 6.73 1.0 % 2.0 % 3.0 % 4.0 % 5.0 % 6.0 % 7.0 % Source: Information Resources, Inc. (IRI) 52-week periods c/c/a/s category. $ Share

  6. Slide 6: Mucinex Total Brand Awareness Grows

    Slide 6: Mucinex Total Brand Awareness Grows

    Mucinex(r) Total Brand Awareness Grows Source: Company sponsored research. 0% 10% 20% 30% 40% 50% 60% 70% 80% 10/1/2005 10/8/2005 10/15/2005 10/22/2005 10/29/2005 11/5/2005 11/12/2005 11/19/2005 11/26/2005 12/3/2005 12/10/2005 12/17/2005 12/24/2005 12/31/2005 1/7/2006 1/14/2006 1/21/2006 1/28/2006 2

  7. Slide 7: Mucinex: Entering New Market Segments

    Slide 7: Mucinex: Entering New Market Segments

    Mucinex(r): Entering New Market Segments Source: $2.9 billion market size as per IRI 52-week period ending 12/25/05, F/D/Mx in c/c/a/s category (excludes Wal-Mart). *Internal estimates Mucinex(r) D Enters the Allergy Segment Market Opportunity: $900 million* Market Opportunity: $2.0 billion*

  8. Slide 8: Mucinex D - Monthly Consumption

    Slide 8: Mucinex D - Monthly Consumption

    Mucinex(r) D 18 ct. - Monthly Consumption Source: IRI 4-week consumption data thru 4/23/06 in c/c/a/s category (excludes Wal-Mart). Nov. 05 Dec. 05 Jan. 06 Feb. 06 Mar. 06 Apr. 06 Units (000's) 71 147 161 175 256 200 0 50 100 150 200 250 300 Nov. Dec. Jan. Feb. Mar. Apr.

  9. Slide 9: Backorder Analysis

    Slide 9: Backorder Analysis

    As of 5/11/06 Backorder ~$1 million Backorder Analysis Backorder @ 12/31/05 $20 million Orders @ 3/31/06 + $67 million Total orders to fill $87 million Actual orders shipped @ 3/31/06 - $76 million Backorder @ 3/31/06 $11 million

  10. Slide 10: Production Capacity Improving

    Slide 10: Production Capacity Improving

    Production Capacity Improving Jan. 2006 Run Rate Current Run Rate Theoretical Run Rate Future Run Rate $250 MM $400 MM $340 - $350 MM Includes existing facilities & equipment $100 MM $200 MM $300 MM $400 MM $500 MM $600 MM $600+ MM Assumes potential addition of new facilities & equipment Source: Int

  11. Slide 11: Children's Mucinex Liquids

    Slide 11: Children's Mucinex Liquids

    Children's Mucinex(r) Liquids

  12. Slide 12: Mucinex Mini-Melts

    Slide 12: Mucinex Mini-Melts

    Mucinex(r) Mini-Melts(tm) 12 convenient pre-measured stick packs per carton

  13. Slide 13: Adams Respiratory Therapeutics

    Slide 13: Adams Respiratory Therapeutics

    ADAMS RESPIRATORY THERAPEUTICS™ I\S

Source: SEC EDGAR · 8-K filed May 11, 2006

More decks from Adams Respiratory Therapeutics Inc